Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Rating of "Moderate Buy" by Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $17.67.

Several analysts have commented on ATEC shares. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research note on Thursday, February 27th. Finally, Piper Sandler increased their price objective on shares of Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th.

Insider Activity at Alphatec

In other Alphatec news, CEO Patrick Miles sold 6,687 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total value of $80,244.00. Following the completion of the transaction, the chief executive officer now owns 5,501,715 shares in the company, valued at approximately $66,020,580. This represents a 0.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Scott Lish sold 27,453 shares of Alphatec stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the sale, the chief operating officer now directly owns 867,677 shares in the company, valued at approximately $9,969,608.73. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 337,321 shares of company stock valued at $3,828,060 over the last three months. 22.80% of the stock is owned by insiders.

Remove Ads

Hedge Funds Weigh In On Alphatec

A number of institutional investors and hedge funds have recently bought and sold shares of ATEC. R Squared Ltd acquired a new position in shares of Alphatec during the 4th quarter valued at $29,000. Comerica Bank grew its holdings in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after acquiring an additional 1,248 shares during the period. Nisa Investment Advisors LLC raised its position in Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after acquiring an additional 4,234 shares in the last quarter. Quarry LP raised its position in Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after acquiring an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC acquired a new stake in Alphatec in the 4th quarter valued at about $50,000. Institutional investors own 66.35% of the company's stock.

Alphatec Price Performance

Shares of NASDAQ ATEC traded up $0.46 during trading on Friday, reaching $9.75. The company had a trading volume of 1,793,242 shares, compared to its average volume of 1,981,174. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec has a twelve month low of $4.88 and a twelve month high of $14.88. The stock has a 50-day moving average price of $10.95 and a two-hundred day moving average price of $8.76. The stock has a market capitalization of $1.41 billion, a PE ratio of -7.62 and a beta of 1.39.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million during the quarter, compared to analysts' expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, sell-side analysts predict that Alphatec will post -1.08 earnings per share for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.